Literature DB >> 18670853

Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET.

Zhaoming Ye1, Jiangjun Zhu, Mei Tian, Hong Zhang, Hongwei Zhan, Chunlei Zhao, Disheng Yang, Weixu Li, Nong Lin.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the potential role of F-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in assessing the chemotherapy response of osteosarcoma when compared with histologically assessed tumor necrosis.
METHODS: Fifteen patients were examined with whole-body FDG-PET prior to and following neoadjuvant therapy. The maximum standard uptake value (SUV max) of tumor and tumor to background ratio (TBR) prior to and following chemotherapy was used for semiquantitative PET imaging analysis. The SUV max of prechemotherapy and post-chemotherapy was recorded as SUV1 and SUV2. TBR1 and TBR2 represented prechemotherapy and post-chemotherapy TBR. TBR was calculated by drawing an identical region of interest over the tumor and the contralateral normal limb or pelvis. Tumor necrosis was classified according to Salzer-Kuntschik's criteria.
RESULTS: Eight patients with more than 90% tumor necrosis were classified as showing good responses and seven patients with less than 90% tumor necrosis as showing poor responses. SUV2/SUV1, TBR2/TBR1, and TBR2 were significantly correlated with the tumor necrosis degree (P < 0.01, P < 0.001, P < 0.001). TBR2/TBR1 were below 0.46 in all the patients with favorable responses, and higher than 0.49 in all the patients with unfavorable responses. However, it was difficult to distinguish good responses from poor responses by SUV2/SUV1.
CONCLUSIONS: FDG-PET is a promising tool to assess the chemotherapy response of osteosarcoma noninvasively. The TBR was better than SUV max in evaluating the chemotherapy response in this study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18670853     DOI: 10.1007/s12149-008-0147-y

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  14 in total

1.  Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.

Authors:  Hyung Jun Im; Tae Sung Kim; Seog-Yun Park; Hye Sook Min; June Hyuk Kim; Hyun Guy Kang; Seung Eun Park; Mi Mi Kwon; Jong Hyung Yoon; Hyeon Jin Park; Seok-ki Kim; Byung-Kiu Park
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-28       Impact factor: 9.236

2.  Positron emission tomography for the evaluation of soft-tissue sarcomas and bone sarcomas.

Authors:  Cristina Nanni; Maria Cristina Marzola; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

3.  18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.

Authors:  Louie L Gaston; Claudia Di Bella; John Slavin; Rodney J Hicks; Peter F M Choong
Journal:  Skeletal Radiol       Date:  2011-02-06       Impact factor: 2.199

Review 4.  PET/CT in primary musculoskeletal tumours: a step forward.

Authors:  A Lakkaraju; C N Patel; K M Bradley; A F Scarsbrook
Journal:  Eur Radiol       Date:  2010-06-25       Impact factor: 5.315

5.  Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma.

Authors:  Junyu Guo; Wilburn E Reddick; John O Glass; Qing Ji; Catherine A Billups; Jianrong Wu; Fredric A Hoffer; Sue C Kaste; Jesse J Jenkins; Ximena C Ortega Flores; Juan Quintana; Milena Villarroel; Najat C Daw
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

6.  Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.

Authors:  Janet F Eary; Ernest U Conrad; Janet O'Sullivan; Douglas S Hawkins; Scott M Schuetze; Finbarr O'Sullivan
Journal:  J Bone Joint Surg Am       Date:  2014-01-15       Impact factor: 5.284

7.  FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas.

Authors:  Matthias R Benz; Johannes Czernin; William D Tap; Jeffrey J Eckardt; Leanne L Seeger; Martin S Allen-Auerbach; Sarah M Dry; Michael E Phelps; Wolfgang A Weber; Fritz C Eilber
Journal:  Sarcoma       Date:  2010-04-18

8.  Tumor necrosis in osteosarcoma: inclusion of the point of greatest metabolic activity from F-18 FDG PET/CT in the histopathologic analysis.

Authors:  Colleen M Costelloe; A Kevin Raymond; Nancy E Fitzgerald; Osama R Mawlawi; Rodolfo F Nunez; John E Madewell; Robyn K Harrell; Roland L Bassett; Edith M Marom
Journal:  Skeletal Radiol       Date:  2009-09-17       Impact factor: 2.199

9.  ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.

Authors:  Chang-Bae Kong; Byung Hyun Byun; Ilhan Lim; Chang Woon Choi; Sang Moo Lim; Won Seok Song; Wan Hyeong Cho; Dae-Geun Jeon; Jae-Soo Koh; Ji Young Yoo; Soo-Yong Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-30       Impact factor: 9.236

Review 10.  Imaging 'the lost tribe': a review of adolescent cancer imaging. Part 1.

Authors:  P D Humphries; I Zerizer
Journal:  Cancer Imaging       Date:  2009-11-06       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.